Sinonep-Allsino Bio Pharmaceutical Co., Ltd. (688076)

Overview

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. is a dynamic force in China's biomedical industry, focusing on the research and development, production, sale, and provision of technical services for peptides and small molecule drugs. With its foundation laid in 2009 and headquartered in Hangzhou, China, the company has carved a niche for itself by developing a range of therapeutic products and services. It caters to various healthcare needs including type 2 diabetes, obesity, and coronavirus treatment options. Incorporating both the manufacturing and research facets of biomedical development, Jiangsu Sinopep-Allsino has expanded its capabilities to include pharmaceutical research, clinical trials, drug registration services, and has ventured into contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) projects, specifically focusing on small molecule chemical active pharmaceutical ingredients (API) and intermediates.

Products and Services

• Formulations:

  The company brings to market various formulations to address a multitude of health concerns. Its portfolio includes thymalfasin products for injection that bolster immune system performance; eptifibatide injections, which are used to prevent blood clots during acute coronary syndrome; alogliptin benzoate tablets for managing type 2 diabetes; and oseltamivir phosphate capsules, targeted at treating influenza. Each product reflects Jiangsu Sinopep-Allsino’s commitment to addressing complex health issues with innovative solutions.

• APIs and Intermediates:

  Jiangsu Sinopep-Allsino is involved in the production of active pharmaceutical ingredients (APIs) and intermediates, providing essential components for the manufacture of various drugs. This segment underscores the company's role in the broader pharmaceutical value chain, supplying quality ingredients for both its products and services to third parties.

• Diabetes and Obesity Drugs:

  Addressing some of the most pressing health challenges of today, the company offers pharmaceutical solutions for managing type 2 diabetes and obesity. Through its innovative drug formulations, it aims to improve the quality of life for individuals suffering from these conditions and reduce the associated healthcare burden.

• Coronavirus Treatment:

  In response to the global pandemic, Jiangsu Sinopep-Allsino swiftly adapted its research and development focus to include drugs aimed at treating coronavirus. By leveraging its biomedical R&D capabilities, the company is contributing to the global effort to combat the spread and impact of COVID-19.

• Pharmaceutical Research, Clinical, and Registration Services:

  The company extends its expertise beyond manufacturing, offering comprehensive services that cover pharmaceutical research, clinical trials, and drug registration. These services facilitate the progression of drugs from concept through to approval, ensuring they meet the regulatory standards and ultimately reach the market.

• CDMO/CMO Projects:

  Jiangsu Sinopep-Allsino takes on contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) projects, particularly for small molecule chemical API and intermediates. This business segment provides integrated services for companies looking to outsource these critical facets of drug development and manufacturing, reinforcing its position as a key player in the pharmaceutical sector.